| Autor: |
Veneziale RW; Pfizer Inc., Pearl River, NY, USA. Robert.veneziale@pfizer.com, Kishnani NS, Nelson J, Resendez JC, Frank DW, Cai XY, Xie L, Cullen C, Frugone CA, Rosenfeld C, Hubbell J, Maxwell SE, Sugarman BJ, Hutchins B, Maneval D, Treinen KA |
| Jazyk: |
angličtina |
| Zdroj: |
Gene therapy [Gene Ther] 2012 Jul; Vol. 19 (7), pp. 742-51. Date of Electronic Publication: 2011 Sep 08. |
| DOI: |
10.1038/gt.2011.116 |
| Abstrakt: |
The safety and toxicokinetics of SCH 721015, an adenovirus encoding the human interferon alpha-2b gene, and Syn3 (SCH 209702), a novel excipient, were assessed in cynomolgus monkeys administered intravesical doses of 2.5 × 10E11 or 1.25 × 10E13 particles SCH 721015 in 25 mg Syn3 or 25 mg Syn3 alone on study days 1 and 91. There was no systemic toxicity. Monkeys dosed with SCH 721015 in Syn3 were positive for SCH 721015-specific DNA in the urine for 2 to 3 days following each dose and had interferon alpha-2b protein in the urine for 1-3 days after a single dose and in fewer animals after a second dose. Intracystic administration was associated with inflammation and focal/multifocal ulceration in the urinary bladder and irritation in the ureters and urethra at necropsy. The physical trauma from catheterization and filling/emptying of the bladder was likely a contributing factor and Syn3 exacerbated the trauma. There was nearly complete resolution of these findings 2 months after the last dose. The trauma to the bladder likely contributed to low, transient systemic exposure to Syn3, SCH 721015 and human interferon protein. The results of this study support the clinical investigation of SCH 721015 in Syn3. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
